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were transplanted with unmanipulated bone marrow and 10 pa-
tients received peripheral blood stem cells either from HLA iden-
tical related (n 44) or unrelated (n 26) or partially mismatched
donor (n  12). Relapse rate was low 16% (13/82) and overall
survival was 52% at a median follow up of 4 years. Risk category
based on the International Prognostic Scoring System (IPSS) at the
time of transplant and median survival respectively was: low (n 
14, median not reached), intermediate-1 (n  39, 110 months),
intermediate-2 (n  19, 27 months) and high (n  10, median not
reached). Predictors evaluated were age, time from diagnosis to
transplant, bone marrow blasts, cytogenetics, risk scoring (IPSS),
FAB classiﬁcation at the time of transplantation and bone marrow
cellularity. Age was not signiﬁcantly associated with other predic-
tors. In univariate analysis, bone marrow blasts, FAB classiﬁcation
and cytogenetics were weakly associated with overall survival. Risk
scoring (IPSS) had same predictive value for survival as bone
marrow blasts and cytogenetics in univariate analysis. In multiva-
riable model, all the predictors had little predictive ability for
survival. Given the low relapse rates in our study, it is not surpris-
ing that there was even less predictive ability in multivariate model
for relapse. In conclusion, a substantial number of patients in all
the risk categories achieved long-term disease free survival. Risk
stratiﬁcation at the time of allogenic transplantation may not pre-
dict the long-term survival and this curative treatment should be
offered to patients in all the risk categories.
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CANADIAN PILOT TRIAL OF HAPLO-IDENTICAL DONOR TRANSPLAN-
TATION
Walker, I.1, Cantin, G.2, Couture, F.2, Dhe´din, N.3, Barty, R.1, Foley,
R.1, Sutherland, R.4, Schultz, K.5 1. McMaster University, Hamilton,
ON, Canada; 2. Universite´ Laval, Quebec City, QC, Canada; 3. Uni-
versite´ de Montre´al, Montreal, QC, Canada; 4. University of Toronto,
Toronto, ON, Canada; 5. University of British Columbia, Vancouver,
BC, Canada; 6. Canadian Blood and Marrow Transplant Group, Van-
couver, BC, Canada.
Background: CBMTG multi-centre pilot study of haplo-iden-
tical donor BMT. AIMS: To assess 1. Ability to collect suitable
graft (CD34  5 x 106/kg and CD3 1 x 105/kg recipient body
weight), 2. Toxicity, 3. Survival to day 100. Eligibility: All
diagnoses and ages; accrual to end after 20 patients with AML in
remission and age less than 55 years. Methods: Preparation: Mod-
iﬁed Perugia regimen, chemotherapy alone; melphalan 140 mg/m2
d -9, thiotepa 10 mg/kg day -7, ﬂudarabine 40 mg/m2 days -7 to -3,
and ATG (Thymoglobulin, Sangstat) days -6 to -2 (total 10.5
mg/kg). Infection prophylaxis: Ganciclovir (GC) 5 mg/kg days
5-20 then x5/week until day100 then x3/week until 210 (subjects
1-3), foscarnet (FC)90 mg/kg days 4-21 then short course pre-
emptive GC or FC (subjects 4-11); ﬂuconazole; cotrimoxazole.
Donors: G-CSF 16 g/kg daily x 5 until second pheresis day.
T-cell depletion: CliniMACS (MiltenyiBiotec). RESULTS:
Eleven (11) patients with AML have been transplanted from 4
centres, 8 female, 3 male, mean age 39 (range 19-60). Disease
status, ﬁrst CR 1/11, second CR 4/11, third CR1/11 , relapse 5/11.
Graft CD34 5 x 106/kg was achieved in all cases, median 13.72
x 106/kg (Q1, Q3: 8.92, 16.61; min 5.59, max 22.2), and CD3 was
1 x 105/kg in all cases, median of 0.49 x104/kg (Q1, Q3: 0.33,
1.64; min 0.22, max 4.10). Ten (10) of the 11 patients have died,
median survival 109 days (Q1, Q3: 67, 153; min 0, max  841).
Survival to day 100 6/11 (55%). Four (4) patients died of leuke-
mic relapse, 6 of infection. Of 6 patients dying of infection, CMV
was a deﬁnite cause in 4. Of 4 dying with relapse, CMV was
signiﬁcant in 1 and asymptomatic in another. Engraftment was
assessed in 10 patients who survived0 days. Granulocyte engraft-
ment (0.5 x 109/L) achieved in all patients, median 12 days (Q1,
Q3: 11, 16; min 8, max 70). Platelet engraftment (20 x 109/L)
achieved in 8 of 10 patients, median of 18 days (Q1, Q3: 14, 37;
min 9, max 97). The two platelet non-engrafters died on days 45
and 61. Toxicity was low, with one toxic death (day 0), and the
Bearman organ toxicity gradings were  grade 2 in all other
patients. Conclusions: Haplo-identical transplantation is feasible,
with a high engraftment rate, minimal toxicity and minimal risk of
graft versus host disease and rejection. However, relapse and CMV
infection were frequent complications in this ultra-high risk group
of patients. Physicians have been reluctant to refer earlier.
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SECOND HEMATOPOIETIC STEM CELL TRANSPLANT USING UNRE-
LATED DONOR UMBILICAL CORD BLOOD CURES 50% OF PEDIATRIC
PATIENTS WITH LEUKEMIA RELAPSING AFTER PRIOR ALLOGENEIC
TRANSPLANT FROM A MATCHED RELATED SIBLING
Staba, S.L., Szabolcs, P., Driscoll, T., Martin, P.L., Kurtzberg, J. Duke
University Medical Center, Durham, NC.
Leukemic relapse after allogeneic stem cell transplant is difﬁcult
to treat and carries a poor prognosis. Cytotoxic therapy has limited
efﬁcacy and subsequent myeloablative transplants are associated
with signiﬁcant treatment related toxicity. We report results of 4
children who relapsed after matched related donor bone marrow
transplants (BMT) and then underwent unrelated donor umbilical
cord blood transplantation (UCBT) following conditioning with
Fludarabine/Melphalan/ATG. Between 7/00 and 5/03 4 children
who experienced leukemic relapse after 1 (n  3) or 2 (n  1)
matched sibling transplants underwent UCBT at Duke University
Medical Center. The average age at the time of UCBT was 7 1/3
years (range 5 1⁄2 to 15 1⁄2 years) old with a median weight of 26 kg
(range 20-45 kg). The median time from initial BMT to UCBT
was 13 months. Two children had ALL (high risk Pre-B ALL
(BMT in CR2, UCBT in CR3); Philadelphia chromosome positive
ALL (BMT in CR 1, DLI in CR2, UCBT in CBR3)) and two had
AML (M1 AML (BMT in CR1 and CR2, UCBT in relapse); M2
AML (BMT in CR2, DLI x 4 in CR3, UCBT in relapse)). All
patients had previously received TBI and were prepared for UCBT
with Fludarabine 25mg/m2 qd x 5, Melphalan 45mg/m2 qd x 3 and
ATG. Cyclosporine and intermediate dose steroids were given for
GVHD prophylaxis. Three children received a 4/6 HLA matched
UCB unit, one a 3/6 HLA matched unit, all with at least one
mismatch at DRB1. The median nucleated cell dose was 9.8 x
107cells/kg (range 5.6–14.4 x 107cells/kg). All 4 demonstrated
complete donor engraftment (absolute neutrophil count greater
than 500/L for three consecutive days) at a median of 24 (range
10–27) days post transplant. Platelet engraftment (untransfused
platelet count 50,000/uL) occurred at a median of 55 days post
transplant. One patient developed acute GVHD (grade 1 skin) and
there was no chronic GVHD seen. The event free survival and
overall survival are both 50%. One child died in remission of
Legionella pneumonia on day96 post transplant, and one died of
relapse on day  424 after UCBT. Two of the 4 patients are
surviving disease free for a median of 775 (range 362-1189) days
post transplant. UCBT after cytoreduction with ﬂudarabine/mel-
phalan/ATG is a viable option as a treatment for leukemic relapse
after matched related allogeneic transplant, with low GVHD rate,
tolerable treatment related mortality and 50% event free survival.
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SIROLIMUS AND TACROLIMUS ALLOW ENGRAFTMENT OF HAPLOIDEN-
TICAL AND OTHER ALTERNATIVE DONOR STEM CELLS AFTER NON-
MYELOABLATIVE CONDITIONING
Claxton, D.F.1, Popescu, D.1, Carraher, M.1, Chiafari, F.A.2, Ehmann,
C.1, Rybka, W.1 1. Penn State Milton S Hershey Medical Center,
Hershey, PA; 2. BRT Laboratories, Baltimore, MD.
Sirolimus (Rapamycin) was added to an established non-myeloa-
blative regimen in order to examine its effects on engraftment and
GVHD. Between 5/2001 and 7/2003 32 patients with advanced
hematological malignancies received alternative donor hematopoi-
etic cell transplantation. Ages ranged from 22-72 (median 62), and
prior therapies from 1-6 (median 3). All received cyclophospha-
mide 1 gram/M2 days -7 and -6, and ﬂudarabine 25 mg/M2 days
-7 through -3 (5 doses). Sirolimus began on day -7 and tacrolimus
on day -4, with methotrexate 5 mg/M2 days 1, 3, and 6 after stem
cell infusion. Graft sources included haploidentical related donors
(3 or 4/6 antigen matched-haplo)-11 cases, 5/6 matched related
donors-8 cases, matched unrelated donors (URD) 12 cases, and in
one case cord blood. Patients receiving haplo stem cells also re-
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ceived anti-thymocyte globulin 30 mg/M2 days -1, 1, 3, and 6.
Engraftment was assessed by whole blood RFLP analysis or XY
FISH (sex mismatched transplants). 30/32 patients, including all 11
haplo-stem cell recipients and all 12 unrelated donor recipients,
engrafted stably. Only transient, incomplete engraftment was seen
in the cord blood recipient and one 5/6 matched recipient. En-
graftment was 90% donor in 19/32 (59%) by day 30 and in 20 of
25 (80%) evaluable patients by day 100. 3/5 patients with subop-
timal engraftment at day 100 had residual circulating CLL cells.
Signiﬁcant renal dysfunction (creatinine 2.5mg/dl) occurred in
15/32 by Day 100 with 2 patients needing dialysis. Renal failure
resolved or abated greatly when tacrolimus was reduced or discon-
tinued. Day 100 transplant related mortality was 3/11 (36%) in
haplo-transplant patients and 1/20 (5%) of URD or 5/6 (low risk)
transplant patients. Acute GVHD (D100) was seen in 21 of 32
patients (66%), but was in general easily managed with steroids,
particularly after low risk transplants. Day 100 transplant related
mortality was 3 of 11 haplo recipients and 1 of 19 low risk patients.
In total 20/32 patients survive at a median 209 days post-trans-
plant. 14 of these 20 patients have been free of progression of
malignancy since transplant and one more has been disease free for
16 months since chemotherapy and donor lymphocyte infusion (ie.
47% currently progression free). Sirolimus added to tacrolimus
and methotrexate appears to facilitate engraftment, minimize graft
versus host disease, and potentially contribute to control of malig-
nant disease.
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PERFORIN, FASL, TNFR1, TWEAK, TRAIL, AND DR3-TL1A ARE NOT
REQUIRED FOR EFFICIENT T CELL MEDIATED RESISTANCE AGAINST
ALLOGENEIC BONE MARROW GRAFTS
Zimmerman, Z.F.1, Jones, A.M.1, Deyev, V.1, Blazar, B.R.2, Yagita,
H.3, Podack, E.R.1, Levy, R.B.1 1. University of Miami School of
Medicine, Miami, FL; 2. University of Minnesota Cancer Center, Mine-
apolis, MN; 3. Juntendo University School of Medicine, Tokyo, Japan.
Immunologic resistance to allogeneic BMT is a major concern in
clinical transplantation, however the molecular pathway(s) medi-
ating this resistance remains unclear. In antigen sensitized CD8
T cell mediated resistance models, mice deﬁcient in perforin and
FasL (B6-cdd), demonstrate efﬁcient rejection of MHC mis-
matched or matched allogeneic BM. Surprisingly, resistance re-
mains intact in the absence of TNFR1 or R2 on donor cells, as well
as in the presence of blocking mAb to TRAIL. This study further
investigates the in vivo effector mechanism(s) in the absence of
these molecules. TWEAK and TL1a are expressed on T cells and
can induce apoptosis when bound to their receptors Fn14 and DR3
respectively. To sensitively examine their role in resistance, block-
ing mAb’s against these ligands were applied with the simultaneous
disruption of perforin, FAS-L, TNF, and TRAIL function. B6-cdd
mice (H-2b) were primed 3 weeks prior to 9.0Gy TBI and trans-
plant with 107 BALB/c (H-2d) TNFR1
/
 or C3H.SW (H-2b)
BM-TCD to assess both MHC mismatched and matched alloge-
neic resistance models. On day 0 and 1 post-BMT, recipients
received 250 ug of -TRAIL (N2B2) and -TWEAK (MTW-1)
mAb. In the MiHA disparate model, mice additionally received
-TL1a mAb (L466) or a control non-blocking mAb to
TL1a(L3A10). Early presence (Day 5) of both multi-potential
CFU-HPP and lineage committed CFU-IL3 progenitor popula-
tions was assessed in recipient spleens. Syngeneic control recipients
exhibited signiﬁcant CFU numbers. In contrast, low or absent
numbers of both CFU progenitor populations were detected in
allogeneic transplants lacking perforin, FasL, and TNFR1. Nota-
bly, mice additionally receiving -TWEAK, TRAIL, and TL1a
also exhibited effective resistance. Therefore, resistance remained
intact despite the simultaneous disruption of these six candidate
effector pathways. These ﬁndings highlight the question, what
precisely, is the role of apoptosis in allogeneic BMT rejection and
also raise the possibility for the involvement of other molecular
players distinct from death inducing ligands. In the MHC disparate
model, marrow from allogeneic B6 bim
/
 donors (kind gift of Dr.
A. Strasser) was effectively rejected in BALB/c recipients. These
observations indicate that if the intrinsic apoptotic pathway is
required for primed T cell resistance against allogeneic progeni-
tors, it is not engaged by Bim. Further studies are in progress to
delineate the contribution of these pathways.
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ACTIVATED ALLOGENEIC NK CELLS AS SUPPRESSORS OF HOST ALLO-
REACTIVE RESPONSES
Liu, H., Welniak, L.A., Murphy, W.J. Universtiy of Nevada, Reno,
Reno, NV.
Nonmyeloablative conditioning regimens offer promise in low-
ering toxicity and extending the applicability of bone marrow
transplantation (BMT). However, despite many means of host
immunosuppression, marrow rejection by host effector cells re-
mains a signiﬁcant concern. As NK cells have been shown to be
potent immunoregulatory cells both in vitro and in vivo, we studied
the ability of activated donor NK cells to speciﬁcally suppress or
delete host reactive immune cells, thereby facilitating engraftment
of donor marrow. We initially tested this hypothesis in vitro.
Activated H2d ALAK (adherent lymphokine activated killer, IL-2
activated T cell depleted bone marrow and spleen cells,98% NK
cells) cells from BALB/c mice signiﬁcantly suppressed the prolif-
eration of H2b splenocytes from C57BL/6 (B6) mice in mixed
lymphocyte responses (MLR) stimulated with irradiated H2d
splenocytes from BALB/c mice (p  0.01). The ability for H2b
splenocytes to kill H2d tumor targets was also signiﬁcantly inhib-
ited by activated H2d ALAK cells (p  0.01). The same number of
H2b ALAK cells or H2d splenocytes did not show the same sup-
pressive effect. Interestingly, in a secondary MLR using an alloge-
neic B6 (H2b) spleen T cell line (stimulated by irradiated BALB/c
splenocytes), activated H2d ALAK cells also greatly suppressed the
activity of the B6 T cells killing H2d tumor targets. These results
suggest that activated H2d ALAK cells can speciﬁcally suppress the
anti-H2d activity of the H2b splenocytes in both primary and
secondary responses. Anti-TGF antibody blockade did not di-
minish this suppressive effect of ALAK cells, suggesting that this
activity was not dependent on TGF secretion. We are currently
testing these ﬁndings in vivo using a nonmyeloablative BMT
model. These in vitro studies suggest that activated donor NK cells
provide a promising way to promote donor engraftment without
involving systemic and nonspeciﬁc suppression of the immune
system.
91
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR THE TREAT-
MENT OF FANCONI ANEMIA USING A FLUDARABINE-BASED CYTORE-
DUCTIVE REGIMEN AND T-CELL DEPLETED GRAFTS FROM ALTERNA-
TIVE DONORS
Boulad, F.1, Auerbach, A.D.2, Kolb, A.1, Small, T.N.1, Prasad, V.1,
Prockop, S.1, Torok-Castanza, J.1, Casson, A.1, Collins, N.H.1, Kernan,
N.A.1, O’Reilly, R.J.1 1. Memorial Sloan-Kettering Cancer Center,
New York, NY; 2. Rockefeller University, New York, NY.
Table. Total Donor Splenic CFU% of Controls
Recipient
(n > 3)
Donor
(107 Bone
Marrow
TCD)
mAb Administered
(D0, D  1)
CFU-
IL3%
Control
CFU-
HPP %
Control
B6-cdd B6 gfp none 100% 100%
B6-cdd
BALB/c
TNFR1/ none <1% <1%
B6-cdd TNFR1/ TRAIL  TWEAK <1% <1%
B6-cdd C3H.SW none <3% <5%
B6-cdd C3H.SW TRAIL  TWEAK <1% <5%
B6-cdd C3H.SW
TRAIL  TWEAK 
TL1a(control) <8% <3%
B6-cdd C3H.SW
TRAIL  TWEAK 
TL1a <7% <1%
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